Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 15, Issue 10, Pages 699-718Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2016.120
Keywords
-
Funding
- Cancer Research UK
- Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre
- MRC [G0502133] Funding Source: UKRI
- Cancer Research UK [11566] Funding Source: researchfish
- Medical Research Council [G0502133] Funding Source: researchfish
Ask authors/readers for more resources
Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available